scholarly journals Stakeholder perspectives on addressing adverse events from adjuvant cancer therapy: A qualitative study

Cancer ◽  
2019 ◽  
Vol 125 (24) ◽  
pp. 4471-4480
Author(s):  
Syril D. Pettit ◽  
Pamela Silberman ◽  
Kristen Hassmiller Lich ◽  
Rebecca A. Kirch ◽  
Steven E. Lipshultz ◽  
...  
Keyword(s):  
Cancer Therapy ◽  
Qualitative Study ◽  
Adverse Events ◽  
Stakeholder Perspectives

scholarly journals The surgical journey: exploring the OR-PACU handover

2021 ◽  
Author(s):  
Marketa Gross
Keyword(s):  
Health Care ◽  
Patient Safety ◽  
Content Analysis ◽  
Qualitative Study ◽  
Adverse Events ◽  
Team Processes ◽  
Team Members ◽  
Handover Process ◽  
Collective Competence ◽  
Transfer Of Information

Patient safety in health care remains a serious concern in Canada. Adverse events can lead to physiological and psychological complications and pose a significant economic burden on the health care system. The purpose of this descriptive qualitative study was to explore the team processes, roles and factors that underpin effective communication between team members during an OR-PACU handover. Content analysis revealed four major categories: Ownership, Distractions and Interruptions, Transfer of Information and Workflow. The results of this study, informed by the Theory of Collective Competence enhance our understanding of the OR-PACU handover and support the need for the development of a structured OR-PACU team handover process.

scholarly journals Implications of aligning full registration of doctors with medical school graduation: a qualitative study of stakeholder perspectives

BMJ Open ◽  
2016 ◽  
Vol 6 (2) ◽  
pp. e010246 ◽  
Author(s):  
K L Mattick ◽  
K Kaufhold ◽  
N Kelly ◽  
J A Cole ◽  
G Scheffler ◽  
...  
Keyword(s):  
Qualitative Study ◽  
Medical School ◽  
Stakeholder Perspectives ◽  
Medical School Graduation ◽  
School Graduation

Comparative nocebo effects in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort—NCCTG 97-24-51 and ACOSOG Z9001 (Alliance A151602).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21545-e21545
Author(s):  
Jennifer Le-Rademacher ◽  
Jared C. Foster ◽  
Josephine Louella Feliciano ◽  
Ajeet Gajra ◽  
Drew K. Seisler ◽  
...  
Keyword(s):  
Adverse Event ◽  
Cancer Therapy ◽  
Adverse Events ◽  
Older Patients ◽  
Nocebo Effect ◽  
Double Blind ◽  
Inert Substance ◽  
Therapeutic Trials ◽  
Nocebo Effects ◽  
Event Rates

e21545 Background: A nocebo is an inert substance that causes adverse events. Although previous studies have examined the favorably positive (placebo) effects of an inert substance, few studies have examined negative (nocebo) effects, particularly in older patients who sometimes experience frequent and severe adverse events from cancer therapy. Methods: This study focused on placebo/nocebo-exposed patients who participated in two double-blind, placebo-controlled, cancer therapeutic studies, namely, North Central Cancer Treatment Group (NCCTG) 97-24-51 and American College of Surgeons Oncology Group (ACOSOG) Z9001, with the goal of reporting comparative, age-based adverse event rates. Results: Among the 446 patients who received placebo/nocebo exclusively, 161 were 65 years of age or older at the time of respective trial entry; 5234 adverse events occurred. Unadjusted adverse event rates did not differ significantly between patients 65 years of age or older and those younger: rate ratio (99% confidence intervals (CI): 1.01 (0.47, 2.02) with similar findings for grade 2 or worse adverse events and for all symptom-driven adverse events (for example, pain, loss of appetite, anxiety). Adjustment for sex, ethnicity, baseline performance score, and trial resulted in no significant age-based rate differences in adverse event rates. Similar findings were observed with an age threshold of 70. Conclusions: A nocebo effect appears to occur irrespective of age. This observation suggests that adverse events should be taken no less seriously in older than in younger cancer patients and that education to manage patients’ expectations from cancer therapy might improve tolerability. [Table: see text]

What puts the adverse in ‘adverse events’? Patients’ perceptions of post-treatment experiences in osteopathy – A qualitative study using focus groups

2012 ◽  
Vol 17 (4) ◽  
pp. 305-311 ◽  
Author(s):  
Dévan Rajendran ◽  
Philip Bright ◽  
Steven Bettles ◽  
Dawn Carnes ◽  
Brenda Mullinger
Keyword(s):  
Qualitative Study ◽  
Adverse Events ◽  
Focus Groups ◽  
Post Treatment

scholarly journals 1864P Expertise for management of immune-related adverse events in cancer therapy: Mapping of French practices

2021 ◽  
Vol 32 ◽  
pp. S1252
Author(s):  
V. Coudert ◽  
N. Penel ◽  
M-C. Le Deley ◽  
C. Delarre ◽  
A. Forestier
Keyword(s):  
Cancer Therapy ◽  
Adverse Events
Sign in / Sign up

Export Citation Format

Share Document